KLCM Advisors Inc. Has $18.96 Million Holdings in Organon & Co. $OGN

Key Points

• KLCM Advisors Inc. increased its stake in Organon & Co. by 3.7% in the first quarter, now owning over 1.27 million shares valued at approximately $18.96 million.
• Organon & Co. reported a quarterly EPS of $1.00, exceeding the expected $0.94, while its quarterly revenue reached $1.59 billion.
• The company recently announced a quarterly dividend of $0.02 per share, with an annualized yield of 0.9%, reflecting a dividend payout ratio of 2.97%.

KLCM Advisors Inc. boosted its position in Organon & Co. (NYSE:OGN - Free Report) by 3.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,273,599 shares of the company's stock after acquiring an additional 45,950 shares during the quarter. Organon & Co. accounts for 2.2% of KLCM Advisors Inc.'s holdings, making the stock its 9th largest holding. KLCM Advisors Inc. owned 0.49% of Organon & Co. worth $18,964,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its stake in Organon & Co. by 8.3% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after acquiring an additional 820,378 shares during the last quarter. LSV Asset Management boosted its position in Organon & Co. by 6.1% in the first quarter. LSV Asset Management now owns 7,980,775 shares of the company's stock valued at $118,834,000 after buying an additional 455,699 shares in the last quarter. Deprince Race & Zollo Inc. boosted its position in Organon & Co. by 7.0% in the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company's stock valued at $70,561,000 after buying an additional 308,267 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Organon & Co. by 23.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock valued at $48,999,000 after buying an additional 629,191 shares in the last quarter. Finally, Private Management Group Inc. boosted its position in Organon & Co. by 1.1% in the first quarter. Private Management Group Inc. now owns 2,142,010 shares of the company's stock valued at $31,895,000 after buying an additional 22,722 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Trading Down 0.3%

OGN stock traded down $0.0250 during midday trading on Tuesday, hitting $9.2550. The stock had a trading volume of 1,657,862 shares, compared to its average volume of 4,491,213. The firm has a market cap of $2.41 billion, a P/E ratio of 3.44, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $23.10. The business has a fifty day moving average price of $9.74 and a two-hundred day moving average price of $11.56.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the business earned $1.12 earnings per share. Organon & Co.'s revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be paid a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Organon & Co.'s payout ratio is 2.97%.

Analysts Set New Price Targets

A number of analysts have weighed in on OGN shares. Piper Sandler cut their target price on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Morgan Stanley cut their target price on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.